{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T14:40:10Z","timestamp":1784385610439,"version":"3.55.0"},"reference-count":14,"publisher":"Japanese Society of Internal Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,2,15]]},"DOI":"10.2169\/internalmedicine.9701-22","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T22:11:48Z","timestamp":1655763108000},"page":"539-543","source":"Crossref","is-referenced-by-count":10,"title":["Hepatocellular Carcinoma Pseudoprogression Involving the Main Portal Vein, Right Ventricular Invasion, and Exacerbation of Lung Metastases in a Patient on Atezolizumab Plus Bevacizumab"],"prefix":"10.2169","volume":"62","author":[{"given":"Ryuta","family":"Shigefuku","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mone","family":"Tsukimoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirono","family":"Owa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Tamai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Tameda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Eguchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushi","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoh","family":"Iwasa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382: 1894-1905, 2020.","DOI":"10.1056\/NEJMoa1915745"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Liu X, Lu Y, Qin S. Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies. Future Oncol 17: 2243-2256, 2021.","DOI":"10.2217\/fon-2020-1290"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. West HJ. JAMA oncology patient page. Immune checkpoint inhibitors. JAMA Oncol 1: 115, 2015.","DOI":"10.1001\/jamaoncol.2015.0137"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375: 1856-1867, 2016.","DOI":"10.1056\/NEJMoa1602252"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Park HJ, Kim KW, Pyo J, et al. Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: a systematic review and meta-analysis. Radiology 297: 87-96, 2020.","DOI":"10.1148\/radiol.2020200443"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Lee DH, Hwang S, Koh YH, et al. Outcome of initial progression during nivolumab treatment for hepatocellular carcinoma: should we use iRECIST? Front Med (Lausanne) 8: 771887, 2021.","DOI":"10.3389\/fmed.2021.771887"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Watanabe Y, Ogawa M, Tamura Y, et al. A case of pseudoprogression in hepatocellular carcinoma treated with atezolizumab plus bevacizumab. J Investig Med High Impact Case Rep 9: 23247096211058489, 2021.","DOI":"10.1177\/23247096211058489"},{"key":"8","unstructured":"8. Mamdani H, Wu H, O'Neil BH, et al. Excellent response to anti-PD-1 therapy in a patient with hepatocellular carcinoma: case report and review of literature. Discov Med 23: 331-336, 2017."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Maesaka K, Sakamori R, Yamada R, et al. Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy. Hepatol Res 52: 298-307, 2021.","DOI":"10.1111\/hepr.13741"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Oxnard GR, Morris MJ, Hodi FS, et al. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst 104: 1534-1541, 2012.","DOI":"10.1093\/jnci\/djs353"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Zhou L, Zhang M, Li R, et al. Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature. J Cancer Res Clin Oncol 146: 3269-3279, 2020.","DOI":"10.1007\/s00432-020-03360-1"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Pfister D, Nunez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592: 450-456, 2021.","DOI":"10.1038\/s41586-021-03362-0"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Llovet JM, Villanueva A. Liver cancer: effect of HCV clearance with direct-acting antiviral agents on HCC. Nat Rev Gastroenterol Hepatol 13: 561-562, 2016.","DOI":"10.1038\/nrgastro.2016.140"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Grierson P, Crites D, Ruzinova MB, et al. Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: a case report of late response after pseudoprogression. Hepatol Commun 2: 148-151, 2018.","DOI":"10.1002\/hep4.1132"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/4\/62_9701-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T03:27:08Z","timestamp":1676690828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/4\/62_9701-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9701-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]},"article-number":"9701-22"}}